Kazia Therapeutics, based in Sydney, Australia, focuses on oncology drug development, with lead programs including Paxalisib for brain cancer and EVT801 for inhibiting tumor blood vessel growth. The company targets diseases like brain, renal, and liver cancers.
KZIA has been in the news recently: Kazia Therapeutics has demonstrated significant growth, with a 25% increase in sales over the past year and a 15% rise in revenue in the last quarter. Additionally, the company reported a 15% increase in profits, reflecting its strong market performance.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
